← Back to Screener
Arcutis Biotherapeutics, Inc. Common Stock (ARQT)
Price$21.35
Value ScoreD
Growth ScoreA
Momentum ScoreC
Favorite Metrics
Price vs S&P 500 (26W)-46.00%
Price vs S&P 500 (4W)-16.18%
VGM Score51.89
Market Capitalization$2.60B
All Metrics
Book Value / Share (Quarterly)$1.52
P/TBV (Annual)20.37x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)367.11%
Cash Flow / Share (Quarterly)$0.14
Price vs S&P 500 (YTD)-39.80%
Gross Margin (TTM)90.94%
Net Profit Margin (TTM)-0.57%
EPS (TTM)$-0.02
10-Day Avg Trading Volume2.00M
EPS Excl Extra (TTM)$-0.02
EPS (Annual)$-0.13
ROI (Annual)-5.41%
Gross Margin (Annual)90.24%
Net Profit Margin (5Y Avg)-19390.75%
Cash / Share (Quarterly)$1.79
Revenue Growth QoQ (YoY)60.07%
ROA (Last FY)-3.73%
Revenue Growth TTM (YoY)95.29%
EBITD / Share (TTM)$0.02
ROE (5Y Avg)-122.20%
Operating Margin (TTM)0.77%
Cash Flow / Share (Annual)$-0.13
P/B Ratio13.71x
P/B Ratio (Quarterly)15.41x
Net Income / Employee (Annual)$-45,600
EV / Revenue (TTM)6.44x
Net Interest Coverage (TTM)-3.70x
ROA (TTM)-0.59%
EV / EBITDA (TTM)832.60x
EPS Incl Extra (Annual)$-0.13
Current Ratio (Annual)3.17x
Quick Ratio (Quarterly)2.26x
3-Month Avg Trading Volume1.49M
52-Week Price Return54.23%
Revenue / Employee (TTM)$1,174,100
Tangible BV / Share (Quarterly)$1.40
P/S Ratio (Annual)6.91x
Asset Turnover (Annual)0.87x
52-Week High$31.77
Operating Margin (5Y Avg)-19198.81%
EPS Excl Extra (Annual)$-0.13
CapEx CAGR (5Y)101.71%
Tangible BV CAGR (5Y)147.92%
26-Week Price Return-32.41%
Quick Ratio (Annual)2.83x
13-Week Price Return-16.03%
Total Debt / Equity (Annual)0.57x
Current Ratio (Quarterly)2.68x
Enterprise Value$2.68B
Asset Turnover (TTM)1.03x
Book Value / Share Growth (5Y)-24.47%
Revenue / Employee (Annual)$1,062,400
Inventory Turnover (Annual)1.98x
Pretax Margin (Annual)-3.98%
Cash / Share (Annual)$1.79
3-Month Return Std Dev56.11%
Net Income / Employee (TTM)$-6,700
ROE (Last FY)-8.52%
Net Interest Coverage (Annual)-1.35x
EPS Basic Excl Extra (Annual)$-0.13
Receivables Turnover (TTM)3.62x
EV / Free Cash Flow (TTM)158.14x
Total Debt / Equity (Quarterly)0.58x
EPS Incl Extra (TTM)$-0.02
Receivables Turnover (Annual)3.43x
ROI (TTM)-0.86%
P/S Ratio (TTM)6.26x
Pretax Margin (5Y Avg)-19390.75%
Revenue / Share (Annual)$2.96
Tangible BV / Share (Annual)$1.42
Forward P/E44.50x
Price vs S&P 500 (52W)26.08%
Year-to-Date Return-28.41%
5-Day Price Return-1.70%
EPS Normalized (Annual)$-0.13
ROA (5Y Avg)-48.11%
Net Profit Margin (Annual)-4.29%
Month-to-Date Return-3.12%
Cash Flow / Share (TTM)$-4.34
EBITD / Share (Annual)$-0.10
Operating Margin (Annual)-3.25%
LT Debt / Equity (Annual)0.57x
P/CF (TTM)96.34x
ROI (5Y Avg)-56.15%
LT Debt / Equity (Quarterly)0.54x
EPS Basic Excl Extra (TTM)$-0.02
P/TBV (Quarterly)16.66x
P/B Ratio (Annual)18.77x
Inventory Turnover (TTM)1.39x
Pretax Margin (TTM)-0.33%
Book Value / Share (Annual)$1.54
Price vs S&P 500 (13W)-26.70%
Beta1.53x
Revenue / Share (TTM)$3.21
ROE (TTM)-1.41%
52-Week Low$12.72
vGradeD
gGradeA
mGradeC
vgmGradeC
Show chart for
Earnings Surprise History
Q1 26-0.09est. -0.08
Analyst Recommendations
Mar 2026
Apr 2026
May 2026
Jun 2026
4.14
4.14
4.14
4.14
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
ARQTArcutis Biotherapeutics, Inc. Common Stock | D | A | C | $21.35 |
| LLYEli Lilly & Co. | D | B | B | $1078.78 |
| JNJJohnson & Johnson | C | C | C | $223.24 |
| ABBVABBVIE INC. | D | C | C | $217.13 |
| MRKMerck & Co., Inc. | C | C | C | $114.70 |
| AZNAstraZeneca PLC | D | B | C | $176.28 |
| NVSNovartis AG | C | C | C | $143.66 |
| NVONovo-Nordisk A/S | B | B | B | $42.00 |
| ABTAbbott Laboratories | C | C | D | $86.99 |
| PFEPfizer Inc. | B | C | C | $25.34 |
| TEVATeva Pharmaceutical Industries Limited American Depositary Shares | C | C | C | $32.83 |
About
Arcutis Biotherapeutics is a commercial-stage biopharmaceutical company developing topical and systemic treatments for immune-mediated dermatological diseases with significant unmet medical needs. Its lead candidate, ZORYVE (roflumilast cream), has completed Phase 3 trials in plaque psoriasis, demonstrating efficacy and favorable tolerability. The company operates in the dermatology space with a differentiated product portfolio focused on this therapeutic area.